To Get Full Access :

NCE-1 Intelligence & Market Opportunity

Hibsago

Bepirovirsen
Solution Injection

Hibsago (bepirovirsen) is an FDA-approved medicine for adults with chronic hepatitis B (CHB). It is used along with existing hepatitis B medicines called nucleos(t)ide analogues. It is approved for eligible adults without cirrhosis who meet specific treatment and viral load requirements.

Hibsago works by targeting the virus’s RNA (genetic material), helping reduce its ability to multiply in the body. It is the first approved medicine that can help some people achieve a functional cure for chronic hepatitis B. A functional cure means the virus remains controlled even after treatment ends, although it may still be present in the body. Discovered and developed by Ionis Pharmaceuticals and marketed by GSK, Hibsago marks an important development in chronic hepatitis B treatment.

Approval Date
20-Oct-26
NCE-1 Date
20-Oct-30
NCE Date
20-Oct-31
Commercial snapshot

Market performance & projections

Revenue ($M)
NA
CAGR (%)
NA
Projected sales, 2026–2032 ($M)
Analyst projection, $M per year
2026
NA
2027
NA
2028
NA
2029
NA
2030
NA
2031
NA
2032
NA
Molecule profile

Details & specifications

Molecule
Bepirovirsen
Innovator
GLAXOSMITHKLINE LLC
Dosage Form
Solution Injection
Strength
150 mg/mL
Therapeutic Category
Usage
To treat chronic hepatitis B virus infection in certain adults without cirrhosis, in combination with existing antiviral therapy
Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

What is Hibsago used for?
How does Hibsago work?
How long is the Hibsago treatment course?
How is Hibsago given?
Hibsago is used to treat chronic hepatitis B in eligible adults. It is given along with existing hepatitis B medicines.
It targets the virus’s RNA (genetic material) to reduce its ability to multiply in the body.
Hibsago is given as a six-month treatment course, taken alongside existing hepatitis B medicines.
Hibsago is given as a weekly injection under the skin. After the first dose, patients may have the option to self-administer.

Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?